Achievments of control of seasonal allergic rhinitis symptoms: the results of open, randomized comparative study of second generation antihistamines



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Seasonal allergic rhinitis (SAR) is one of the most common allergic diseases. The first choice for control of SAR symptoms is the second-generation antihistamines (AHP-II). The aim of this study was to evaluate the comparative efficacy of ebastine 20 mg/day, cetirizine 10 mg/day, and loratadine 10 mg/day in adult patients with mild symptoms of SAR due to pollen grass allergy. 30 patients aged 18 to 65 years who received treatment for 14 days took part in the study. The duration of the study for one patient varied from 25 to 28 days. As a result, the efficiency of all three AHP II in the control of mild symptoms of SAR was demonstrated. However, the analysis of the scales (TNSS and TNNSS) after the end of the 14-day treatment period revealed that compared to patients treated with loratadine and cetirizine (TNSS scale (p=0,0303), TNNSS (p=0,0091) the best results were observed in the group of patients taking ebastine. Moreover, patients who received the ebastine experienced a statistically insignificant but steady tendency to decrease the level of eosinophilic cationic protein (ECP) in nasal flushing (-37,9% of the baseline values), in contrast to loratadine and cetirizine. All drugs showed a high safety profile. To conclude, the investigated AHPs -II are effective and safe in control of mild symptoms of SAR in adult patients, though the rate of onset of the effect and its level for nasal and non nasal symptoms was significantly higher in patients receiving ebastine 20 mg compared to cetirizine 10 mg and loratadine 10 mg.

Full Text

Restricted Access

About the authors

O S Bodnya

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: os.bodnya@yandex.ru

N M Nenasheva

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

G V Andrenova

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

D O Siniavkin

City Clinical Hospital of the Department of Health of Moscow № 52

Y V Bodnya

M.V. Lomonosov Moscow State University

E T Kubanova

M.V. Lomonosov Moscow State University

References

  1. Бодня О.С. Фенотипы ринита - дифференциальный диагноз. Эффективная фармакотерапия. Аллергология и иммунология. 2016, № 1, с. 50-63.
  2. Дробик О.С. Аллергический ринит: современные подходы к диагностике и терапии. Эффективная фармакотерапия. 2014, № 29, с. 54-59.
  3. Ненашева Н.М. Достижение контроля аллергического ринита с помощью ступенчатой терапии. Эффективная фармакотерапия. Пульмонология и оториноларингология. 2015, № 1, с. 14-22.
  4. Allergic rhinitis and its impact on asthma (ARIA). WHO initiative. 2001-2010.
  5. Дробик O.C., Насунова А.Ю. Аллергический ринит -взгляд аллерголога. Вестник отоларингологии. 2014, № 2, с. 82-85.
  6. Van Cauwenberge P., Bachert C., Bousquet J. et al. Consensus statement on the treatment of allergic rhinitis EAACI Position paper. Allergy. 2000, v. 55, p. 116-134.
  7. Ненашева Н.М., Ильина Н.И., Бердникова Н.Г. Эффективность и безопасность препарата Момат Рино (мометазона фуроат в виде спрея назального дозированного) у взрослых пациентов с круглогодичным аллергическим ринитом: результаты рандомизированного открытого мультицентрового клинического исследования. Consilium Medicum. 2016, № 18, с. 102-109.
  8. Бодня О.С., Ненашева Н.М. В помощь практикующему врачу: ведение пациентов с аллергическим ринитом на амбулаторном этапе. Астма и аллергия. 2015, v. 4, p. 28-34.
  9. Canonica G.W., Bousquet J., Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007, v. 62, p. 17-25.
  10. Fortea J., Mora S., Artes M. Ebasstine fast-dissolving tablets versus regular tablets: Acceptability and preference in patients with allergic rhinitis. Expert. Rev. Clin. Pharmacol. 2008, v. 1, p. 381-389.
  11. Ratner P., Falques M., Chuecos F. et al. Meta-analysis of the Efficacy of Ebastine 20 mg Compared to Loratadine 10 mg and Placebo in the Symptomatic Treatment of Seasonal Allergic Rhinitis. Int. Arch. Allergy Immunol. 2005, v. 138, p. 312-318.
  12. Campbell A., Michel F.B., Bremard-Oury C. et al. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs. 1996, v. 52, p. 15-19.
  13. Horiguchi T., Tachikawa S., Kasahara J. et al. Effect of Ebastine on Serum Eosinophil Cationic Protein Levels in Patients with Bronchial Asthma. Clin. Drug. Invest. 1999, v. 17, p. 435-440.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2017



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies